ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

daratumumab

Also written as “Daratumumab”, “Daratumumab SC” and “Daratumumab IV”.

Its studies are mostly in Multiple Myeloma · Amyloidosis · Precursor Cell Lymphoblastic Leukemia-Lymphoma · Myelodysplastic Syndromes · Lymphoma, Mantle-Cell, led by 4 companies.

Drug pageDaratumumab: every studyAll 219 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 4, since Nov 29, 201833 company-led studies, 6 open or runningNext primary completion: Mar 8, 2027 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Johnson & Johnsonits history only284 open or runningphase 4since Nov 29, 2018Dec 14, 2007Jan 31, 2029phase 3 · NCT05438043
Bristol-Myers Squibbits history only31 open or runningphase 3since Aug 16, 2018May 12, 2016none ahead
Amgen10 open or runningphase 3since May 9, 2017May 9, 2017none ahead
Celltrionits history only11 open or runningphase 3since Apr 29, 2025Apr 29, 2025Mar 8, 2027phase 3 · NCT06952478

Also a collaborator on its studies: Karyopharm Therapeutics.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Amgen only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. May 9, 2017First study: phase 3 study in Multiple MyelomaFirst studyNCT03158688 · 466 enrolled · United States, Australia, Austria and more

TargetBeta

CD38 →read by rule
“A human immunoglobulin G1-kappa (IgG1k) monoclonal antibody directed against the cell surface glycoprotein CD38, with immunomodulating and antineoplastic activities”NCIt, by rule
“Lymphocyte differentiation antigen CD38 inhibitor”ChEMBL 37, by rule

Other programs on CD38

ProgramCompanyFurthest phaseStudies
isatuximabruleSanofiphase 323
felzartamabruleBiogenphase 315
mezagitamabruleTakedaphase 311
lumrotatugruleKeymed Biosciencesphase 310
Anti-CD38 Monoclonal Antibody SCTC21CruleSinocelltech Groupphase 35
sanritatugruleHangzhou Sumgen Biotechphase 35
CID-103ruleCASI Pharmaceuticalsphase 23
Anti-BCMA/CD38/CD3 Trispecific Antibody ABBV-2001AbbViephase 22
Anti-CD38 Monoclonal AntibodyruleChongqing Genrix Biopharmaceuticalphase 21
Anti-CD38 Antibody-drug Conjugate ABBV-438AbbViephase 11

Studies

The one study Amgen leads. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT03158688Multiple Myeloma · United States, Australia, Austria and more3CompletedJul 14, 2019466

How it is read

Names in the registry

  • “Daratumumab”, 32 entries
  • “daratumumab”, 3 entries
  • “Daratumumab SC”, 3 entries
  • “Daratumumab IV”, 2 entries
  • “CT-P44(Daratumumab)”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.